Daurismo (glasdegib) Patient Assistance Program
Don’t let the high cost of brand specialty AML therapy disrupt your treatment. We help eligible patients access Daurismo (glasdegib) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Daurismo (glasdegib) is FDA-approved in combination with low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults ≥75 years or who have comorbidities precluding intensive induction chemotherapy. It is a Hedgehog pathway inhibitor.
- Without assistance, Daurismo costs commonly run approximately $20,000–$26,000 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Daurismo for a flat $69.95 per month — our advocacy team manages the entire enrollment, refills, and renewal process.
- There is no generic Daurismo in the U.S. as of 2026. For unfit AML patients, alternatives include venetoclax (Venclexta) + azacitidine or decitabine (often preferred — strong evidence with VIALE-A trial), azacitidine alone, decitabine alone (with Inqovi oral option now), low-dose cytarabine alone. Venetoclax-based therapy is now generally preferred over LDAC + Daurismo in many centers.
What Is Daurismo Prescription Assistance Program?
The Daurismo Prescription Assistance Program is a manufacturer-sponsored initiative that provides Daurismo at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for unfit AML patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology coordination, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and re-certification.
Pharmacy Price Comparison
- Without assistance, Daurismo costs roughly $20,000–$26,000/month. A Patient Assistance Program is the meaningful path forward — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$25,000 | Save substantially |
| CVS Pharmacy | ~$26,000 | Save substantially |
| Walmart | ~$21,000 | Save substantially |
| Costco | ~$20,500 | Save substantially |
Specialty Pharmacy | ~$22,000 | Save substantially |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Daurismo Prescription Program?
The Patient Assistance Program is free to apply for and provides Daurismo at no medication cost if approved. Our $69.95/month service covers full advocacy. With venetoclax-based regimens (Venclexta + azacitidine/decitabine) now generally preferred for unfit AML, we’ll help your oncologist determine the best path.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Daurismo:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $20,000–$26,000 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Daurismo assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Daurismo Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Daurismo:
Daurismo (glasdegib) is a once-daily oral Hedgehog pathway inhibitor used in combination with low-dose cytarabine for newly-diagnosed AML in patients ≥75 years or with significant comorbidities precluding intensive chemotherapy. The Hedgehog pathway plays a role in leukemic stem cell maintenance.
How Daurismo Works:
Acute Myeloid Leukemia (AML) is driven by leukemic stem cells that resist conventional chemotherapy, largely due to the aberrant activation of the Hedgehog signaling pathway. Glasdegib selectively inhibits Smoothened (SMO) to block this pathway and target these resistant stem cells. When combined with low-dose cytarabine (LDAC), it has been shown to improve overall survival in unfit AML patients compared to LDAC alone. However, this specific regimen has been largely superseded by more effective venetoclax-based combinations.
Form and use:
Daurismo is administered as a 100 mg oral tablet taken once daily, and it can be consumed with or without food. It is taken in tandem with concomitant LDAC, which is given as a 20 mg subcutaneous injection twice daily for 10 days of every 28-day cycle. This combination therapy is continued until the disease progresses or unacceptable toxicity occurs. Patients undergoing this treatment require regular ECG and electrolyte monitoring due to the risk of QT prolongation.
Generic availability:
As of 2026, there is no generic version of Daurismo available in the United States. For unfit AML patients, preferred alternative treatments include venetoclax combined with either azacitidine or decitabine due to their strong clinical outcomes. Depending on the patient’s specific AML genetics, other targeted oral options are also utilized. These include IDH1/IDH2 inhibitors like Tibsovo and Idhifa, as well as FLT3 inhibitors like Xospata and Rydapt.
Warnings:
Daurismo carries significant warnings for QT prolongation, requiring electrolyte correction and the avoidance of other QT-prolonging drugs. It also poses severe risks for embryo-fetal toxicity, mandating strict REMS programs, pregnancy testing, and rigorous contraception for female patients. Because of semen-mediated fetal exposure, male patients must also use condoms during therapy and for at least 30 days after stopping. Common side effects include anemia, fatigue, muscle spasms, alopecia, and dysgeusia.
FAQ (Frequently Asked Questions)
How Much Does Daurismo Cost Without Insurance?
Daurismo costs approximately $20,000–$26,000 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Daurismo at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Should I Be On Venetoclax Instead?
Discuss with your oncologist. The VIALE-A trial showed venetoclax (Venclexta) + azacitidine produces strong outcomes in unfit AML — generally better than LDAC + Daurismo. Most oncologists now favor venetoclax-based regimens for unfit AML in 2026, with Daurismo reserved for specific scenarios or contraindications to venetoclax. The choice depends on your specific situation, comorbidities, and AML genetics.
Why Glasdegib + LDAC?
This combination was approved based on the BRIGHT AML 1003 trial, which showed improved overall survival vs. LDAC alone in patients unfit for intensive induction chemotherapy. The combination targets both bulk leukemia (LDAC) and leukemic stem cells (glasdegib via hedgehog pathway). The regimen is well-tolerated for elderly/unfit patients but has been largely superseded by venetoclax-based regimens in current practice
Will I Have Side Effects?
Common side effects: anemia, fatigue, nausea, decreased appetite, peripheral edema, muscle spasms, dysgeusia (taste changes), alopecia (hair loss). The taste changes are characteristic of hedgehog pathway inhibitors and can affect food intake and quality of life. Tell your oncologist about significant side effects — dose adjustments may help.
Why Do I Need ECGs?
Daurismo can prolong the QT interval. ECG is checked at baseline and periodically. Avoid other QT-prolonging drugs where possible. Correct any electrolyte abnormalities (low potassium, magnesium) before and during therapy. Tell your prescriber about any palpitations or syncope.
Can I Get Daurismo Through The PAP If I Have Medicare?
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
What If My Application Is Denied?
If denied, we explore alternatives — switching to venetoclax + azacitidine (VIALE-A regimen, often preferred), other AML-targeted therapies based on genetics (IDH1/IDH2/FLT3 inhibitors), the manufacturer’s copay program for commercially insured patients, or independent foundations such as the Leukemia & Lymphoma Society, PAN Foundation, or HealthWell Foundation. If we cannot find a path, you won’t be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Daurismo, our team may be able to help you access assistance programs — or guide you to venetoclax-based therapy if it’s a better fit. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.